98 related articles for article (PubMed ID: 16445374)
1. MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma.
Morgenstern DA; Anderson J
Expert Rev Anticancer Ther; 2006 Feb; 6(2):217-24. PubMed ID: 16445374
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy.
Tonelli R; McIntyre A; Camerin C; Walters ZS; Di Leo K; Selfe J; Purgato S; Missiaglia E; Tortori A; Renshaw J; Astolfi A; Taylor KR; Serravalle S; Bishop R; Nanni C; Valentijn LJ; Faccini A; Leuschner I; Formica S; Reis-Filho JS; Ambrosini V; Thway K; Franzoni M; Summersgill B; Marchelli R; Hrelia P; Cantelli-Forti G; Fanti S; Corradini R; Pession A; Shipley J
Clin Cancer Res; 2012 Feb; 18(3):796-807. PubMed ID: 22065083
[TBL] [Abstract][Full Text] [Related]
3. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells.
Paffhausen T; Schwab M; Westermann F
Cancer Lett; 2007 May; 250(1):17-24. PubMed ID: 17141950
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma.
Alaminos M; Mora J; Cheung NK; Smith A; Qin J; Chen L; Gerald WL
Cancer Res; 2003 Aug; 63(15):4538-46. PubMed ID: 12907629
[TBL] [Abstract][Full Text] [Related]
5. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma.
Woo CW; Tan F; Cassano H; Lee J; Lee KC; Thiele CJ
Pediatr Blood Cancer; 2008 Feb; 50(2):208-12. PubMed ID: 17420990
[TBL] [Abstract][Full Text] [Related]
6. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
7. Molecularly guided therapy of neuroblastoma: a review of different approaches.
Tonini GP; Pistoia V
Curr Pharm Des; 2006; 12(18):2303-17. PubMed ID: 16787256
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
Chesler L; Schlieve C; Goldenberg DD; Kenney A; Kim G; McMillan A; Matthay KK; Rowitch D; Weiss WA
Cancer Res; 2006 Aug; 66(16):8139-46. PubMed ID: 16912192
[TBL] [Abstract][Full Text] [Related]
9. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
10. Retinoic acid induced downregulation of MYCN is not mediated through changes in Sp1/Sp3.
Kanemaru KK; Tuthill MC; Takeuchi KK; Sidell N; Wada RK
Pediatr Blood Cancer; 2008 Apr; 50(4):806-11. PubMed ID: 17554788
[TBL] [Abstract][Full Text] [Related]
11. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
12. Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma.
Fulda S; Poremba C; Berwanger B; Häcker S; Eilers M; Christiansen H; Hero B; Debatin KM
Cancer Res; 2006 Oct; 66(20):10016-23. PubMed ID: 17047064
[TBL] [Abstract][Full Text] [Related]
13. Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization.
Stock C; Bozsaky E; Watzinger F; Poetschger U; Orel L; Lion T; Kowalska A; Ambros PF
Am J Pathol; 2008 Jan; 172(1):203-14. PubMed ID: 18165268
[TBL] [Abstract][Full Text] [Related]
14. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target.
Mercado GE; Xia SJ; Zhang C; Ahn EH; Gustafson DM; Laé M; Ladanyi M; Barr FG
Genes Chromosomes Cancer; 2008 Jun; 47(6):510-20. PubMed ID: 18335505
[TBL] [Abstract][Full Text] [Related]
15. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model.
Blanc E; Goldschneider D; Ferrandis E; Barrois M; Le Roux G; Leonce S; Douc-Rasy S; Bénard J; Raguénez G
Am J Pathol; 2003 Jul; 163(1):321-31. PubMed ID: 12819037
[TBL] [Abstract][Full Text] [Related]
16. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
[TBL] [Abstract][Full Text] [Related]
18. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of MYCN amplified, progressive stage 4S neuroblastoma in a neonate with hepatic artery embolization in addition to multimodality treatment.
Boztug K; Kiely E; Roebuck DJ; Gaze M; Begent J; Brock P; Michalski A
Pediatr Blood Cancer; 2006 Feb; 46(2):253-7. PubMed ID: 15926157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
